clinical trial · NCT07104565
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Immune ThrombocytopeniaINCA000585
brief summary
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
started
Dec 29, 2025
primary completion
Sep 23, 2027
completion
Mar 9, 2028
last updated
Jun 16, 2026
official title
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol